microRNAs 424 and 503 are mediators of the anti-proliferative and anti-invasive action of the thyroid hormone receptor beta

Oncotarget

Volumn 5, Issue 10, 2014, Pages 2918-2933

  Ruiz Llorente, Lidia ^a   Ardila González, Soraya ^a   Fanjul, Luisa F ^a   Martínez Iglesias, Olaia ^a   Aranda, Ana ^a  

^a CSIC   (Spain)

Author keywords

Hepatocarcinoma and breast cancer cells; Invasion; MicroRNA 424; MicroRNA 503; Proliferation; Thyroid hormone receptor

Indexed keywords

LIOTHYRONINE; MICRORNA; MICRORNA 424; MICRORNA 503; THYROID HORMONE RECEPTOR BETA; UNCLASSIFIED DRUG; MIRN424 MICRORNA, HUMAN; MIRN503 MICRORNA, HUMAN;

ANTIINVASIVE ACTION; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER CELL LINE; CELL CYCLE REGULATION; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; EXTRAVASATION; GENE OVEREXPRESSION; GENE REPRESSION; GENETIC TRANSCRIPTION; HISTONE ACETYLATION; HORMONE ACTION; HORMONE INHIBITION; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL; HYPOTHYROIDISM; IN VIVO STUDY; LIVER CANCER CELL LINE; LUNG CANCER CELL LINE; PROMOTER REGION; RECEPTOR BINDING; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; TUMOR GROWTH; TUMOR INVASION; XENOGRAFT; ANIMAL; CHROMATIN IMMUNOPRECIPITATION; DNA MICROARRAY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE; NUDE MOUSE; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; MICE; MICE, NUDE; MICRORNAS; NEOPLASM INVASIVENESS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; THYROID HORMONE RECEPTORS BETA; TRANSCRIPTIONAL ACTIVATION;

EID: 84902089966     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1577     Document Type: Article

References (51)

1. Aranda A and Pascual A. Nuclear hormone receptors and gene expression. Physiological reviews. 2001; 81(3):1269-1304.
2. Aranda A, Martinez-Iglesias O, Ruiz-Llorente L, Garcia-Carpizo V and Zambrano A. Thyroid receptor: roles in cancer. Trends Endocrinol Metab. 2009; 20(7):318-324.
3. Pascual A and Aranda A. Thyroid hormone receptors, cell growth and differentiation. Biochimica et biophysica acta. 2013; 1830(7):3908-3916.
4. Yen CC, Huang YH, Liao CY, Liao CJ, Cheng WL, Chen WJ and Lin KH. Mediation of the inhibitory effect of thyroid hormone on proliferation of hepatoma cells by transforming growth factor-beta. J Mol Endocrinol. 2006; 36(1):9-21.
5. Garcia-Silva S, Martinez-Iglesias O, Ruiz-Llorente L and Aranda A. Thyroid hormone receptor beta1 domains responsible for the antagonism with the ras oncogene: role of corepressors. Oncogene. 2011; 30(7):854-864.
6. Chen RN, Huang YH, Yeh CT, Liao CH and Lin KH. Thyroid hormone receptors suppress pituitary tumor transforming gene 1 activity in hepatoma. Cancer research. 2008; 68(6):1697-1706.
7. Ledda-Columbano GM, Perra A, Loi R, Shinozuka H and Columbano A. Cell proliferation induced by triiodothyronine in rat liver is associated with nodule regression and reduction of hepatocellular carcinomas. Cancer research. 2000; 60(3):603-609.
8. Perra A, Kowalik MA, Pibiri M, Ledda-Columbano GM and Columbano A. Thyroid hormone receptor ligands induce regression of rat preneoplastic liver lesions causing their reversion to a differentiated phenotype. Hepatology. 2009; 49(4):1287-1296.
9. Chan IH and Privalsky ML. Thyroid hormone receptors mutated in liver cancer function as distorted antimorphs. Oncogene. 2006; 25(25):3576-3588.
10. Chan IH and Privalsky ML. Thyroid hormone receptor mutants implicated in human hepatocellular carcinoma display an altered target gene repertoire. Oncogene. 2009; 28(47):4162-4174.
11. Lin KH, Wu YH and Chen SL. Impaired interaction of mutant thyroid hormone receptors associated with human hepatocellular carcinoma with transcriptional coregulators. Endocrinology. 2001; 142(2):653-662.
12. Lin KH, Zhu XG, Hsu HC, Chen SL, Shieh HY, Chen ST, Mcphie P and Cheng SY. Dominant negative activity of mutant thyroid hormone alpha1 receptors from patients with hepatocellular carcinoma. Endocrinology. 1997; 138(12):5308-5315.
13. Conde I, Paniagua R, Zamora J, Blanquez MJ, Fraile B, Ruiz A and Arenas MI. Influence of thyroid hormone receptors on breast cancer cell proliferation. Ann Oncol. 2006; 17(1):60-64.
14. Li Z, Meng ZH, Chandrasekaran R, Kuo WL, Collins CC, Gray JW and Dairkee SH. Biallelic inactivation of the thyroid hormone receptor beta1 gene in early stage breast cancer. Cancer research. 2002; 62(7):1939-1943.
15. Silva JM, Dominguez G, Gonzalez-Sancho JM, Garcia JM, Silva J, Garcia-Andrade C, Navarro A, Munoz A and Bonilla F. Expression of thyroid hormone receptor/erbA genes is altered in human breast cancer. Oncogene. 2002; 21(27):4307-4316.
16. Martinez-Iglesias O, Garcia-Silva S, Regadera J and Aranda A. Hypothyroidism enhances tumor invasiveness and metastasis development. PLoS One. 2009; 4(7):e6428.
17. Martinez-Iglesias O, Garcia-Silva S, Tenbaum SP, Regadera J, Larcher F, Paramio JM, Vennstrom B and Aranda A. Thyroid hormone receptor beta1 acts as a potent suppressor of tumor invasiveness and metastasis. Cancer research. 2009; 69(2):501-509.
18. Sayed D and Abdellatif M. MicroRNAs in development and disease. Physiological reviews. 2011; 91(3):827-887.
19. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136(2):215-233.
20. Guo H, Ingolia NT, Weissman JS and Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature. 2010; 466(7308):835-840.
21. Baek D, Villen J, Shin C, Camargo FD, Gygi SP and Bartel DP. The impact of microRNAs on protein output. Nature. 2008; 455(7209):64-71.
22. Fabian MR and Sonenberg N. The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC. Nature structural & molecular biology. 2012; 19(6):586-593.
23. Esquela-Kerscher A and Slack FJ. Oncomirs-microRNAs with a role in cancer. Nature reviews Cancer. 2006; 6(4):259-269.
24. Garzon R and Marcucci G. Potential of microRNAs for cancer diagnostics, prognostication and therapy. Current opinion in oncology. 2012; 24(6):655-659.
25. Kong YW, Ferland-Mccollough D, Jackson TJ and Bushell M. microRNAs in cancer management. The lancet oncology. 2012; 13(6):e249-258.
26. Finnerty JR, Wang WX, Hebert SS, Wilfred BR, Mao G and Nelson PT. The miR-15/107 group of microRNA genes: evolutionary biology, cellular functions, and roles in human diseases. Journal of molecular biology. 2010; 402(3):491-509.
27. Linsley PS, Schelter J, Burchard J, Kibukawa M, Martin MM, Bartz SR, Johnson JM, Cummins JM, Raymond CK, Dai H, Chau N, Cleary M, Jackson AL, Carleton M and Lim L. Transcripts targeted by the microRNA-16 family cooperatively regulate cell cycle progression. Molecular and cellular biology. 2007; 27(6):2240-2252.
28. Liu Q, Fu H, Sun F, Zhang H, Tie Y, Zhu J, Xing R, Sun Z and Zheng X. miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes. Nucleic acids research. 2008; 36(16):5391-5404.
29. Rissland OS, Hong SJ and Bartel DP. MicroRNA destabilization enables dynamic regulation of the miR-16 family in response to cell-cycle changes. Molecular cell. 2011; 43(6):993-1004.
30. Griffiths-Jones S, Saini HK, van Dongen S and Enright AJ. miRBase: tools for microRNA genomics. Nucleic acids research. 2008; 36(Database issue):D154-158.
31. Caporali A and Emanueli C. MicroRNA-503 and the extended microRNA-16 family in angiogenesis. Trends in cardiovascular medicine. 2011; 21(6):162-166.
32. Chamorro-Jorganes A, Araldi E, Penalva LO, Sandhu D, Fernandez-Hernando C and Suarez Y. MicroRNA-16 and microRNA-424 regulate cell-autonomous angiogenic functions in endothelial cells via targeting vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1. Arteriosclerosis, thrombosis, and vascular biology. 2011; 31(11):2595-2606.
33. Forrest AR, Kanamori-Katayama M, Tomaru Y, Lassmann T, Ninomiya N, Takahashi Y, de Hoon MJ, Kubosaki A, Kaiho A, Suzuki M, Yasuda J, Kawai J, Hayashizaki Y, Hume DA and Suzuki H. Induction of microRNAs, mir-155, mir-222, mir-424 and mir-503, promotes monocytic differentiation through combinatorial regulation. Leukemia. 2010; 24(2):460-466.
34. Ghosh G, Subramanian IV, Adhikari N, Zhang X, Joshi HP, Basi D, Chandrashekhar YS, Hall JL, Roy S, Zeng Y and Ramakrishnan S. Hypoxia-induced microRNA-424 expression in human endothelial cells regulates HIF-alpha isoforms and promotes angiogenesis. The Journal of clinical investigation. 2010; 120(11):4141-4154.
35. Nakashima T, Jinnin M, Etoh T, Fukushima S, Masuguchi S, Maruo K, Inoue Y, Ishihara T and Ihn H. Down-regulation of mir-424 contributes to the abnormal angiogenesis via MEK1 and cyclin E1 in senile hemangioma: its implications to therapy. PLoS One. 2010; 5(12):e14334.
36. Pouliot LM, Chen YC, Bai J, Guha R, Martin SE, Gottesman MM and Hall MD. Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family. Cancer research. 2012; 72(22):5945-5955.
37. Xu J, Li Y, Wang F, Wang X, Cheng B, Ye F, Xie X, Zhou C and Lu W. Suppressed miR-424 expression via upregulation of target gene Chk1 contributes to the progression of cervical cancer. Oncogene. 2013; 32(8):976-987.
38. Long XH, Mao JH, Peng AF, Zhou Y, Huang SH and Liu ZL. Tumor suppressive microRNA-424 inhibits osteosarcoma cell migration and invasion via targeting fatty acid synthase. Experimental and therapeutic medicine. 2013; 5(4):1048-1052.
39. Zhou J and Wang W. Analysis of microRNA expression profiling identifies microRNA-503 regulates metastatic function in hepatocellular cancer cell. Journal of surgical oncology. 2011; 104(3):278-283.
40. Zhou B, Ma R, Si W, Li S, Xu Y, Tu X and Wang Q. MicroRNA-503 targets FGF2 and VEGFA and inhibits tumor angiogenesis and growth. Cancer letters. 2013; 333(2):159-169.
41. Sarkar S, Dey BK and Dutta A. MiR-322/424 and-503 are induced during muscle differentiation and promote cellcycle quiescence and differentiation by down-regulation of Cdc25A. Molecular biology of the cell. 2010; 21(13):2138-2149.
42. Imig J, Motsch N, Zhu JY, Barth S, Okoniewski M, Reineke T, Tinguely M, Faggioni A, Trivedi P, Meister G, Renner C and Grasser FA. microRNA profiling in Epstein-Barr virus-associated B-cell lymphoma. Nucleic acids research. 2011; 39(5):1880-1893.
43. York B and O'Malley BW. Steroid receptor coactivator (SRC) family: masters of systems biology. The Journal of biological chemistry. 2010; 285(50):38743-38750.
44. Faraoni I, Laterza S, Ardiri D, Ciardi C, Fazi F and Lo-Coco F. MiR-424 and miR-155 deregulated expression in cytogenetically normal acute myeloid leukaemia: correlation with NPM1 and FLT3 mutation status. Journal of hematology & oncology. 2012; 5:26.
45. Pallasch CP, Patz M, Park YJ, Hagist S, Eggle D, Claus R, Debey-Pascher S, Schulz A, Frenzel LP, Claasen J, Kutsch N, Krause G, Mayr C, Rosenwald A, Plass C, Schultze JL, et al. miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia. Blood. 2009; 114(15):3255-3264.
46. Wang X, Wang J, Ma H, Zhang J and Zhou X. Downregulation of miR-195 correlates with lymph node metastasis and poor prognosis in colorectal cancer. Med Oncol. 2012; 29(2):919-927.
47. Aarts M, Linardopoulos S and Turner NC. Tumour selective targeting of cell cycle kinases for cancer treatment. Current opinion in pharmacology. 2013.
48. Harper JW and Elledge SJ. The DNA damage response: ten years after. Molecular cell. 2007; 28(5):739-745.
49. Emmrich S and Putzer BM. Checks and balances: E2F-microRNA crosstalk in cancer control. Cell Cycle. 2010; 9(13):2555-2567.
50. Ramsay RG and Gonda TJ. MYB function in normal and cancer cells. Nature reviews Cancer. 2008; 8(7):523-534.
51. Garcia-Obregon S, Alfonso-Sanchez MA, Perez-Miranda AM, Vidales C, Arroyo D and Pena JA. Genetic position of Valencia (Spain) in the Mediterranean basin according to Alu insertions. American journal of human biology: the official journal of the Human Biology Council. 2006; 18(2):187-195.